I am putting my gf (Barbie) on cjc no dac (50-100mcg) and ipam (100-200mcg) twice daily. That is an extremely safe stack with minimal side effects and should just give great results
Ipamorelin is a growth hormone releasing peptide. It stimulates the body to release more human growth hormone and igf-1. Increases in gh and igf-1 can result in many benefits including:
- Builds Lean Tissue
- Lowers Body Fat
- Improved Recovery from training
- anti aging
- Improves Mood and Sleep Patterns
Ipamorelin is similar to other GHRP's such as GHRP-2 and GHRP-6. However Ipamorelin does not cause sudden spikes in prolactin or cortisol like GHRP-2 and GHRP-6 can do. Both of those hormones when elevated can cause negative side effects. Cortisol is a steroid hormone that is released when stressed and can be very catabolic. Prolactin counteracts the effect of dopamine, which is responsible for sexual arousal. Elevated prolactin can cause a variety of unwanted physical and psychological effects.
Raun K et al. (1998) highlighted ipamorelin's beneficial effects over the other ghrp's. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6. In conscious swine, gh release after ipamorelin injection was high and again vey similar to GHRP6. In the same study GHRP-2 displayed higher potency but lower efficacy. The specificity for GH release was studied in swine. They found none of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even when extremely high doses of were used. Ipamorelin was the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.
A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. However ipameolin is slow in its delivery unlike GHRPs which spike GH levels at a faster rate. This another notable difference when researching ghrp's. Moreover it has been shown that Ipamorelin is able to exert a dynamic control effect on the somatotroph population and on GH hormone content (Jiménez-Reina L et al. 2002).
A variety of promising effects have been displayed when ipamorelin has been studied. Adeghate E et al. (2004) examined the effect ipamorelin had on insulin secretion from pancreatic tissue fragments of normal and diabetic rats. Ipamorelin evoked significant (p<0.04) increases in insulin secretion from the pancreas of normal and diabetic rats. It was shown that ipamorelin stimulates insulin release through the calcium channel and the adrenergic receptor pathways.
Nitrogen balance is very important in humans. A positive value is often found during periods of growth, tissue repair or pregnancy. This means that the intake of nitrogen into the body is greater than the loss of nitrogen from the body, so there is an increase in the total body pool of protein. A negative value can be associated with burns, fevers, wasting diseases and other serious injuries and during periods of fasting. This means that the amount of nitrogen excreted from the body is greater than the amount of nitrogen ingested. Aagaard NK et al. (2009) studied the metabolic effects of Ipamorelin on selected hepatic measures of alpha-amino-nitrogen conversion during steroid-induced catabolism. Prednisolone was the steroid used to induce this catabolism. In prednisolone treated rats ipamorelin reduced CUNS by 20% (p<0.05), decreased the expression of urea cycle enzymes, neutralised N-balance, and normalized or improved organ N-contents. Therefore accelerated nitrogen wasting in the liver and other organs caused by prednisolone treatment was counteracted by treatment with Ipamorelin.
Ipamorelin is ideal for pre bed dosing due to it's long active life and minimal effect on hunger levels. When other GHRP's are used such as GHRP 2/6 they can cause a sudden increase in appetite which can be awkward pre bed. Doses as little as 200mcg are highly effective but I feel Ipamorelin truly shines when you boom dose it. I have gone up to as much as 1mg pre bed and that was incredible. Although for most a dose of 500mcg would be more than enough when combined with a GHRH. My favourite peptide cycle to date has been CJC-1295 DAC with GHRP-2 through the day. Then a high dose of Ipam used pre bed.
Finally just want to list what I feel is a key advantage ipamorelin has over GH injections in a research environment. Unlike GH injections it does not shut down the bodys natural production of this hormone, it just enhances it. In the long run this is a huge factor and I feel future studies will highlight the importance of this in relation to health.
1. Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H (2009) Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. PMID: 19231263 [PubMed - indexed for MEDLINE]
2. Adeghate E, Ponery AS (2004) Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. PMID: 15665799 [PubMed - indexed for MEDLINE]
3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998) Ipamorelin, the first selective growth hormone secretagogue. PMID: 9849822 [PubMed - indexed for MEDLINE]
4. Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G (2002) Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. PMID: 12168778 [PubMed - indexed for MEDLINE]
I tried to get my wife to do this stack too. But, she's freaked out by the labels saying, "For research and development only"
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
Jiménez-Reina L1, Cañete R, de la Torre MJ, Bernal G.
Growth hormone (GH) is secreted in the anterior pituitary gland by the somatotroph cells. Secretion is regulated by growth hormone releasing hormone (GHRH) and somatostatin. Morever, GH secretagogues (GHS) can exert a considerable effect on GH secretion. In order to determine the effects of chronic treatment with the GHS Ipamorelin on the composition of the somatotroph cell population and on somatotroph GH content, an in vitro analysis was performed of the percentage of somatotroph cells (% of total), the ratio of different GH cell types (strongly/weakly-staining) and individual GH content, in pituitary cell cultures obtained from young female rats receiving Ipamorelin over 21 days (Ipamorelin group) and the effects were compared with those of GHRH (GHRH group) or saline (saline group). The ultrastructure of somatotroph cells did not change, but the volume density of secretion granules was increased (P<0.05) by previous in vivo Ipamorelin or GHRH treatment. In 3-day basal pituitary cell monolayer cultures, the percentage of somatotroph cells showed no modifications between groups, nor was there any change in the ratio of strongly/weakly immunostaining GH cells. In the Ipamorelin group alone, in vitro treatment with Ipamorelin (10(-8) M), or GHRP 6 (10(-8) M), or GHRH (10(-8) M) for 4 hours, increased the percentage of somatotroph cells, without modifying the ratio of strongly/weakly immunostained GH cells. Basal intracellular GH content in somatotroph cells over 4 hours was lower in the Ipamorelin group and the GHRH group than in the saline group. Only in the Ipamorelin group did Ipamorelin (10(-8) M), GHRP 6 (10(-8) M) and GHRH (10(-8) M) prompt increased intracellular GH content. These data suggest that, at least in the young female rat, the GHS Ipamorelin is able to exert a dynamic control effect on the somatotroph population and on GH hormone content.
PMID: 12168778 [PubMed - indexed for MEDLINE]